Can a patient assistance program reduce the proportion of people with idiopathic pulmonary fibrosis (IPF) who stop taking pirfenidone?
Not Applicable
- Conditions
- Idiopathic pulmonary fibrosisRespiratoryOther interstitial pulmonary diseases with fibrosis
- Registration Number
- ISRCTN15587630
- Lead Sponsor
- F. Hoffmann-La Roche AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 189
Inclusion Criteria
1. Participants diagnosed with idiopathic pulmonary fibrosis
2. Participants in whom their treating physician has decided, in partnership with them, to prescribe pirfenidone in accordance with the approved labelling
3. Written informed consent provided
Exclusion Criteria
1. Concurrent participation in a clinical trial
2. Participants unable to give consent as per investigator criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method